Phibro Anl Htlh A Cm (PAHC) 19.95 $PAHC Phibro Animal

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 7:12 PM

Phibro Anl Htlh A Cm (PAHC) 19.95 $PAHC

Phibro Animal Health Corporation Submits Studies Reaffirming Safety of Mecadox(R)
GlobeNewswire - 2 hrs 17 mins ago
Phibro Animal Health Corporation (NASDAQ

AHC) today submitted to the Food and Drug Administration (FDA) the findings of several new studies confirming the safety of carbadox, which is used to control bacterial diseases in pigs.
PAHC: 19.95 (+0.07)

Strategy To YieldBoost Phibro Animal Health Corp. From 2.2% To 11.5% Using Options
StockOptionsChannel.com - Tue Jun 28, 10:36AM CDT
Shareholders of Phibro Animal Health Corp. looking to boost their income beyond the stock's 2.2% annualized dividend yield can sell the December covered call at the $22.50 strike and collect the premium based on the 80 cents bid, which annualizes to...
PAHC: 19.95 (+0.07)

Velocity Increases the Value of Cloud Applications for Phibro Animal Health
Marketwire Canada - Tue Jun 07, 7:38AM CDT
VCAMP(TM) Platform Takes JD Edwards to the Cloud, Adding Analytics and Proactive Alerting to Increase Agility and Reduce Risk
PAHC: 19.95 (+0.07)

Oregon livestock company wins trade-secret injunction
Capital Press - Sun Jun 05, 2:56PM CDT
SALEM, Ore. (AP) — An Oregon livestock company has won an injunction against a former employee accused of stealing trade secrets to start his own company in China.
PAHC: 19.95 (+0.07)

Phibro Animal Health Corporation Announces Gerald Carlson Retirement, Larry Miller Promotion
GlobeNewswire - Tue May 31, 3:15PM CDT
Phibro Animal Health Corporation (NASDAQ

AHC) today announced that Gerald Carlson, Chief Operating Officer, will retire after 14 years with Phibro, effective July 1, 2016.
PAHC: 19.95 (+0.07)

Phibro Animal Health Corporation to Participate at the Macquarie Global Emerging Leaders Conference
GlobeNewswire - Fri May 20, 3:00PM CDT
Phibro Animal Health Corporation (NASDAQ

AHC) Chief Financial Officer Richard Johnson will address financial analysts and portfolio managers at the Macquarie Global Emerging Leaders Conference.
PAHC: 19.95 (+0.07)

Phibro Animal (PAHC) Misses Q3 Earnings on Low Revenues
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:00AM CDT
Phibro (PAHC) ended the fiscal third quarter on a disappointing note, with its bottom line lagging the Zacks Consensus Estimate by a solid margin and its revenues failing to expand on a year-over-year basis.
SRDX: 24.79 (+0.13), PAHC: 19.95 (+0.07), BAX: 46.49 (-0.16), LMAT: 13.64 (-0.06)

Phibro posts 3Q profit
Automated Insights - Mon May 09, 6:22PM CDT
TEANECK, N.J. (AP) _ Phibro Animal Health Corp. (PAHC) on Monday reported fiscal third-quarter profit of $18.6 million.
PAHC: 19.95 (+0.07)

Phibro Animal Health Corporation Reports Third Quarter
GlobeNewswire - Mon May 09, 3:15PM CDT
Phibro Animal Health Corporation (NASDAQ

AHC) today announced its financial results for its third quarter ended March 31, 2016.
PAHC: 19.95 (+0.07)

Phibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Wed Apr 13, 12:00PM CDT
Phibro Animal Health Corporation (NASDAQ

AHC) Chairman, President and Chief Executive Officer Jack Bendheim and Chief Financial Officer Richard Johnson will address financial analysts and investors at the Bank of America Merrill Lynch 2016 Health Care Conference.
PAHC: 19.95 (+0.07)

Phibro Animal Declines as FDA Moves to Revoke Mecadox
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 12:50PM CDT
A recent reexamination by the FDA has led the authority to question Phibro Animal Health Corporation's (PAHC) Mecadox drug's safety.
PAHC: 19.95 (+0.07), BAX: 46.49 (-0.16), LMAT: 13.64 (-0.06), OFIX: 46.98 (+0.28)

Phibro Animal Health Corporation Reiterates Safety of Mecadox(R)
GlobeNewswire - Fri Apr 08, 1:59PM CDT
(NASDAQ

AHC) Today, the Food and Drug Administration (FDA) issued a press release stating its intention to take the initial steps in the process to rescind its approval of Mecadox(R) (carbadox). Mecadox has been approved and sold in the United States for more than 40 years and is a widely-used treatment for controlling bacterial diseases including Salmonella and swine dysentery. Mecadox is not used in human medicine and the class of drug is not considered a medically important antimicrobial. The approved Mecadox label requires a 42-day withdrawal period pre-harvesting, and to date we have not seen any hazardous residues of carbadox being detected from pig meat treated in accordance with the approved label.
PAHC: 19.95 (+0.07)

Phibro: Animal Health Grows amid Competition from Generics
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 1:35PM CDT
On Apr 7, 2016, we issued an updated research report on New Jersey-based Phibro Animal Health (PAHC).
CAPR: 4.10 (+0.08), CSII: 19.32 (-0.30), PAHC: 19.95 (+0.07), BAX: 46.49 (-0.16)

Phibro Animal Health Corporation to Host Webcast and Conference Call on March 2016 Quarterly Financial Results
GlobeNewswire - Wed Mar 30, 3:00PM CDT
Phibro Animal Health Corporation (NASDAQ

AHC) will host a webcast and conference call to review third quarter financial results. A news release containing quarterly results is expected to be issued after the market closes on Monday, May 9, 2016.
PAHC: 19.95 (+0.07)

Phibro Animal Health (PAHC) in Focus: Stock Jumps 5.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 7:35AM CDT
Phibro Animal Health Corporation (PAHC) was a big mover last session, as the company saw its shares rise over 5% on the day.
PAHC: 19.95 (+0.07), ATRC: 15.31 (+0.11)

Phibro (PAHC): Animal Health Grows Despite Currency Woes
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 1:30PM CDT
On Mar 17, 2016, we issued an updated research report on Phibro Animal Health Corporation (PAHC).
PAHC: 19.95 (+0.07), BAX: 46.49 (-0.16), HRC: 51.04 (-0.33), OSUR: 6.56 (+0.12)

Phibro Animal Health Corporation Declares Quarterly Dividend
GlobeNewswire - Mon Feb 08, 3:30PM CST
The Board of Directors of Phibro Animal Health Corporation (Nasdaq

AHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on March 23, 2016, to stockholders of record at the close of business on March 2, 2016.
PAHC: 19.95 (+0.07)

Phibro Animal Health Corporation Announces Closing of Acquisition of Business of MVP Laboratories, Inc.
GlobeNewswire - Mon Jan 25, 3:30PM CST
Phibro Animal Health Corporation ("Phibro"

(NASDAQ

AHC) today announced it has completed its purchase of the assets of MVP Laboratories, Inc. ("MVP"

, a developer, manufacturer and marketer of livestock vaccines, vaccine adjuvants and other products based in Omaha, Nebraska. Phibro previously announced an agreement to purchase the assets of MVP Laboratories, Inc. on January 12, 2016.
PAHC: 19.95 (+0.07)

Is Phibro Animal Health (PAHC) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 7:46AM CST
Phibro Animal Health is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
PAHC: 19.95 (+0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....